Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...

Bibliográfalaš dieđut
Váldodahkkit:	Chakrabarti, S, Hale, G, Waldmann, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2004

Geahča maid

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Dahkki: Watson, C, et al.
Almmustuhtton: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Dahkki: Hale, G, et al.
Almmustuhtton: (2002)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
Dahkki: Phuong-Thu T Pham, et al.
Almmustuhtton: (2008-12-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Dahkki: Clatworthy, MR, et al.
Almmustuhtton: (2009)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Dahkki: Watson, C, et al.
Almmustuhtton: (2005)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
Dahkki: Potter, M, et al.
Almmustuhtton: (2000)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
Dahkki: Lv Meng, et al.
Almmustuhtton: (2012-03-01)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
Dahkki: Fibbe, W, et al.
Almmustuhtton: (1993)

CAMPATH-1 antibodies in stem-cell transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (2001)

Where do we go from here?
Dahkki: Rai, Vijesh
Almmustuhtton: (2016)

Expert Systems: Where Are We? And Where Do We Go from Here?
Dahkki: Davis, et al.
Almmustuhtton: (2004)

Editorial: Where Are We Now and Where Do We Go From Here
Dahkki: Gabriele Manganaro
Almmustuhtton: (2022-01-01)

Availability of Campath-1 antibodies for bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
Dahkki: Maria Kadma da Silva Carriço, et al.
Almmustuhtton: (2003-06-01)

Tractography: where do we go from here?
Dahkki: Jbabdi, S, et al.
Almmustuhtton: (2011)

Afterword: Where Do We Go from Here?
Dahkki: Kimberly Vinall, et al.
Almmustuhtton: (2017-01-01)

Transplantation tolerance: the big picture. Where do we stand, where should we go?
Dahkki: Waldmann, H
Almmustuhtton: (2017)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
Dahkki: Cull, G, et al.
Almmustuhtton: (1999)

Commentary: Retinoblastoma management–Where are we and where do we go from here?
Dahkki: P Mahesh Shanmugam
Almmustuhtton: (2020-01-01)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
Dahkki: Lundin, J, et al.
Almmustuhtton: (2001)

How Did We Get Here and Where are We Going?
Dahkki: Georgina CHAMBERS
Almmustuhtton: (2022-09-01)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
Dahkki: Russell, N, et al.
Almmustuhtton: (1999)

CAMPATH-1H in inflammatory arthritis.
Dahkki: Watts, R, et al.
Almmustuhtton: (1993)

COVID-19 - where do we go from here?
Dahkki: Lee, Pei Hua, et al.
Almmustuhtton: (2020)

Propriospinal myoclonus: where do we go from here?
Dahkki: Brown, P
Almmustuhtton: (2014)

Oil prices : where do we go from here?/
Dahkki: 284295 Zanoyan, Vahan
Almmustuhtton: (1986)

Math anxiety : where do we go from here? /
Dahkki: 297422 Hunt, Glen E.

Advanced ceramics : where do we go from here?/
Dahkki: 348668 Smith, Vincent, et al.

Multiple Sclerosis: Where do we go from here?
Dahkki: Marta Tejera-Alhambra, et al.
Almmustuhtton: (2016-07-01)

Calibration research: Where do we go from here?
Dahkki: Linda eBol, et al.
Almmustuhtton: (2012-07-01)

PITUITARY INCIDENTALOMAS – WHERE DO WE GO FROM HERE?
Dahkki: Syed Ali Imran
Almmustuhtton: (2016-08-01)

Developmental Dyslexia: Where Do We Go from Here?
Dahkki: Paul E. Engelhardt
Almmustuhtton: (2020-03-01)

OMR At Crossroads; Where Do We Go From Here ?
Dahkki: Mangala Meti
Almmustuhtton: (2004-01-01)

Topological photonics: Where do we go from here?
Dahkki: Segev Mordechai, et al.
Almmustuhtton: (2020-10-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2003)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (2001)

CAMPATH: from concept to clinic.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (2005)

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Dahkki: Cull, G, et al.
Almmustuhtton: (2000)